article thumbnail

STAT+: Eli Lilly’s stock falls after 2024 guidance misses forecasts

STAT

Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales of its diabetes and obesity drugs Mounjaro and Zepbound. The company also expects revenue from all of 2024 to be $45 billion, lower than the range of $45.4 billion in revenue, less than the $13.9

Diabetes 269
article thumbnail

Lilly launches Mounjaro (tirzepatide), offers new treatment option for obesity and type 2 diabetes

Express Pharma

It is a treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Mounjaro is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. per cent and 2.1

Diabetes 101
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Megablockbusters are the holy grail. Here’s how drugmakers are getting there.

PharmaVoice

Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercialization Leadership Manufacturing Patient Pharma Policy & Regulation Research & Development Library Events Press Releases PharmaVoice 100 Nominate 2024 PV100 2023 PV100 Sign up Search Sign up Search An article from Megablockbusters are the holy grail.

Diabetes 147
article thumbnail

Eli Lilly’s Zepbound holds possibility to dominate obesity market

Express Pharma

On December 20, 2024, tirzepatide also received FDA approval for obstructive sleep apnea. Indeed, semaglutide is approved for type 2 diabetes, obesity, and cardiovascular risk factors, and is in development for four additional indications, including chronic kidney disease. While Wegovy caused an average weight loss of 13.7

Diabetes 105
article thumbnail

AI-driven drug discovery, precision medicine, and sustainable manufacturing can redefine the pharma industry

Express Pharma

What are the top 3 trends that defined pharma manufacturing in India and globally in 2024? In 2024, the pharmaceutical manufacturing landscape underwent transformative changes, driven by technological innovations, regulatory adaptations, and evolving global demands.

article thumbnail

Tranq dope (fentanyl-xylazine combination): A new horizon in opioid withdrawal treatment

ALiEM - Pharm Pearls

2024 study [16]. Last Words Substance use disorders (SUD) are similar to other chronic relapsing medical conditions such as diabetes mellitus, congestive heart failure/cardiomyopathy, chronic obstructive pulmonary disorder, and cancer. 2024 Oct 8:S0735-6757(24)00523-0. Published online September 4, 2024. 2024.10.006].

article thumbnail

STAT+: Pharmalittle: We’re reading about Novo and GLP-1 compounding, Paxlovid and long Covid, and more

STAT

The latest attempt focuses on liraglutide, an older, once-daily injectable product sold as Victoza and Xultophy for diabetes and Saxenda for obesity.